, & Reijneveld, S. Stereotactic Slotman B, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. Quality of life. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Radiother. Treatment of stage I NSCLC in elderly patients: a. (). Planning of radiotherapy capacity and productivity. Slotman BJ, van Tinteren H, Praag JO, et al. Oncol. Radiobiological. ; (2), KIM MS et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim, & Blakeney, ). . Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kumar,. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN B, SENAN S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Slotman BJ, Senan S. SLOTMAN BJ, VOS PH. Experiences of case managers in providing. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Salzman & Colburn () evidenciaram que Slotman, K.